tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Hypothermia D007035 19 associated lipids
Hypotension D007022 41 associated lipids
Hypoglycemia D007003 13 associated lipids
Hypertension, Renal D006977 9 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypertension D006973 115 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypersensitivity D006967 22 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperkalemia D006947 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hypercalcemia D006934 13 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Hyperalgesia D006930 42 associated lipids
Hydronephrosis D006869 4 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
HIV Seropositivity D006679 15 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Herpes Labialis D006560 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hepatitis C D006526 7 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Hemorrhage D006470 15 associated lipids
Hemophilia A D006467 10 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Hemolysis D006461 131 associated lipids
Hematuria D006417 13 associated lipids
Hematoma D006406 5 associated lipids
Hematologic Diseases D006402 3 associated lipids
Heart Injuries D006335 6 associated lipids
Heart Failure D006333 36 associated lipids
Cardiomegaly D006332 31 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Headache D006261 4 associated lipids
Hand Injuries D006230 1 associated lipids
Hand Dermatoses D006229 5 associated lipids
Hallucinations D006212 4 associated lipids
Gynecomastia D006177 6 associated lipids
Graves Disease D006111 6 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Gout D006073 4 associated lipids
Glycosuria D006029 10 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Glomerulonephritis D005921 35 associated lipids
Gliosis D005911 6 associated lipids
Glioma D005910 112 associated lipids
Gingivitis D005891 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Castleman Disease D005871 3 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Gastroenteritis D005759 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Foot Dermatoses D005533 3 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Folliculitis D005499 7 associated lipids
Fistula D005402 8 associated lipids
Fibrosis D005355 23 associated lipids
Fever D005334 35 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Fatty Liver D005234 48 associated lipids
Fatigue D005221 10 associated lipids
Facial Neoplasms D005153 3 associated lipids
Facial Dermatoses D005148 7 associated lipids
Eye Diseases D005128 12 associated lipids
Exanthema D005076 11 associated lipids
Esophageal Perforation D004939 1 associated lipids
Erythroplasia D004919 1 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Erythema Nodosum D004893 5 associated lipids
Erythema D004890 22 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Epididymitis D004823 1 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Encephalitis D004660 15 associated lipids
Edema D004487 152 associated lipids
Eczema D004485 4 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Earache D004433 2 associated lipids
Dyspnea D004417 10 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tesi RJ et al. Conversion of pancreas transplants to FK 506 from CsA. 1995 Transplant. Proc. pmid:8539828
Sterneck M et al. Steroid withdrawal in long-term liver transplant recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750398
Kobayashi M et al. HLA-DR matching effect in orthotopic liver transplantation under FK 506. 1993 Transplant. Proc. pmid:7679812
Burke GW et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. 1995 Transplant. Proc. pmid:8539872
Charpentier B Induction versus non-induction protocols in anti-calcineurin-based immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750425
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Watanabe K et al. Fate of long-surviving allografts in tolerant recipients induced by fractionated lymphoid irradiation, donor bone marrow cell infusion, and FK 506 after retransplantation in dogs. 1993 Transplant. Proc. pmid:7679813
Ueki M et al. Peritoneal-omental pouch as a site for islet allotransplantation. 1994 Transplant. Proc. pmid:7513462
Miura S et al. Long-term results of spousal renal donor transplants with donor-specific blood transfusions. 2001 Nov-Dec Transplant. Proc. pmid:11750463
Strasser S et al. The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. 1991 Transplant. Proc. pmid:1703709
van Duijnhoven E et al. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. 1998 Transplant. Proc. pmid:9636515
Borro JM et al. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome. 2007 Transplant. Proc. pmid:17889206
Ryu S and Yasunami Y Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. 1991 Transplant. Proc. pmid:1703710
Christiaans M et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. 1998 Transplant. Proc. pmid:9636516
Sancho Calabuig A et al. Very low-grade proteinuria at 3 months posttransplantation is an earlier marker of graft survival. 2009 Jul-Aug Transplant. Proc. pmid:19715850
Herrero JC et al. Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications. 2002 Transplant. Proc. pmid:11959201
Zeevi A et al. Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. 1990 Transplant. Proc. pmid:1689902
Imventarza O et al. Renal transplantation in baboons under FK 506. 1990 Transplant. Proc. pmid:1689903
Monden M et al. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. 1990 Transplant. Proc. pmid:1689904
Bonet H et al. Survival of patients transplanted with alcoholic hepatitis plus cirrhosis as compared with those with cirrhosis alone. 1993 Transplant. Proc. pmid:7680145
Melo MJ et al. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study. 2015 Transplant. Proc. pmid:26036484
Santos T et al. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients. 2015 Transplant. Proc. pmid:26036483
Pichard L et al. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. 1991 Transplant. Proc. pmid:1721279
Takeda M et al. Methotrexate in rescue therapy for xenotransplanted lungs in primates. 1996 Transplant. Proc. pmid:8623402
Langrehr JM et al. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. 1998 Transplant. Proc. pmid:9636583
Nakao A et al. Combined effect of donor-specific bone marrow transplantation via portal vein and FK506 on small bowel transplantation in the rat. 2000 Transplant. Proc. pmid:11120044
Luk JM et al. Immunosuppressive effects of Tripterygium wilfordii polysaccharide on LPS-stimulated human monocytes. 2000 Transplant. Proc. pmid:11120045
Viganó J et al. Incidence of graft rejection in small bowel transplanted pigs after immunosuppression withdrawal. 2006 Jul-Aug Transplant. Proc. pmid:16908291
Undre NA et al. Pharmacokinetics of tacrolimus: clinically relevant aspects. 1999 Transplant. Proc. pmid:10576037
Higuchi K et al. FK506 induces the atrophy of enteric ganglia in small bowel transplantation, which can be prevented by the neuropeptide bombesin. 2006 Jul-Aug Transplant. Proc. pmid:16908293
Mayer AD Four-year follow-up of the European Tacrolimus Multicenter Renal Study. 1999 Transplant. Proc. pmid:10576038
Yilmaz A et al. Severe angioedema caused by banana allergy under tacrolimus immunosuppression. 2005 Transplant. Proc. pmid:16387091
Lai WJ et al. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? 2004 Transplant. Proc. pmid:15518744
Barten MJ et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. 2005 Transplant. Proc. pmid:16387162
Chueh SC et al. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. 2004 Transplant. Proc. pmid:15518745
Colak H et al. Relationship of Interleukin-10 and Transforming Growth Factor-β Levels With Short-Term Graft Function After Kidney Transplantation. 2015 Transplant. Proc. pmid:25964218
Kawauchi M et al. Cardiac xenotransplantation from pig to Japanese monkey with splenectomy, tacrolims, filtration plasmapheresis, and nafamstat mesilate. 1994 Transplant. Proc. pmid:7518105
Platz KP et al. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. 1995 Transplant. Proc. pmid:7533357
Andersson J et al. The effects of FK 506 on cytokine production are dependent on the mode of cell activation. 1991 Transplant. Proc. pmid:1721311
Li D et al. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. 2006 Transplant. Proc. pmid:17112846
Antoniou EA et al. Effect of donor-specific transfusion in combination with FK 506 in rat cardiac allotransplantation. 1999 Transplant. Proc. pmid:10578296
Abecassis MM et al. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis. 2008 Transplant. Proc. pmid:18589126
Li J et al. Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. 2008 Transplant. Proc. pmid:18589137
Hassoun Z et al. The choice of calcineurin inhibitor does not influence centrilobular necrosis after orthotopic liver transplantation. 2002 Transplant. Proc. pmid:12176464
Oike F et al. Complete withdrawal of immunosuppression in living donor liver transplantation. 2002 Transplant. Proc. pmid:12176465
Kawano K et al. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. 1995 Transplant. Proc. pmid:7533410
Akita K and Mandel TE Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. 1993 Transplant. Proc. pmid:7692650
Tanabe M et al. Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 1995 Transplant. Proc. pmid:7533411
Opelz G Evaluation of immunosuppressive induction regimens in renal transplantation. Collaborative Transplant Study. 1998 Transplant. Proc. pmid:9865286
Tzakis AG et al. FK 506 versus cyclosporine in pediatric liver transplantation. 1991 Transplant. Proc. pmid:1721343
Moffatt SD et al. Comparative efficacy of liposomal FK506 with FK506. 1998 Transplant. Proc. pmid:9865297
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Niel OR et al. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors. 2009 Transplant. Proc. pmid:19857743
Marin M et al. Factors influencing the onset of diabetes mellitus after kidney transplantation: a single French center experience. 2005 Transplant. Proc. pmid:15919484
Jacques F et al. Comparison of cyclosporine and tacrolimus in combination with rabbit antithymocyte immunoglobulins as induction therapy in cardiac transplantation. 2009 Transplant. Proc. pmid:19857745
Rossi G et al. Small bowel transplantation under oral immunosuppression: experimental study in the pig. 1997 Transplant. Proc. pmid:9142285
Spada M et al. Tacrolimus and mycophenolate mofetil in pig small bowel transplantation: different protocols and their outcome. 1997 Transplant. Proc. pmid:9142286
Ronchetti F et al. Intestinal damage evaluation in swine allograft small bowel through hyaluronic acid quantification. 1997 Transplant. Proc. pmid:9142293
Rabkin JM et al. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. 2002 Transplant. Proc. pmid:12176483
Liu Y et al. Delayed Initiation of Tacrolimus Is Safe and Effective in Renal Transplant Recipients With Delayed and Slow Graft Function. 2018 Transplant. Proc. pmid:30316359
Morphopathological findings of renal allografts under FK 506 therapy. Japanese FK 506 Study Group. 1994 Transplant. Proc. pmid:7520614
Goh BL and Tan SY FK506 "rescue" therapy complicated by renal tubular acidosis in renal allograft recipients. 1998 Transplant. Proc. pmid:9838575
Morris SM et al. Disruption of renal function and gene expression by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721375
Lagodziński Z et al. Effect of FK 506 on B-cell responses. 1991 Transplant. Proc. pmid:1703359
Tacrolimus in renal transplantation: a comparison of induction vs noninduction therapy (triple therapy): three-month results. 1999 Feb-Mar Transplant. Proc. pmid:10083131
Takayama K et al. Hepatocyte growth factor and vascular endothelial growth factor expression in pig-to-primate xenotransplanted hearts. 2000 Transplant. Proc. pmid:10936314
Izbicki G et al. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine. 2002 Transplant. Proc. pmid:12493439
Meiser BM et al. Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123150
Shimizu T et al. Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts. 2008 Transplant. Proc. pmid:18790237
Ushigome H et al. Immunosuppression in cadaveric renal transplant recipients from non-heart-beating donors in a single center. 2002 Transplant. Proc. pmid:12176533
Nanmoku K et al. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy. 2008 Transplant. Proc. pmid:18790241
Citterio F et al. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up. 2002 Transplant. Proc. pmid:12176535
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Pirsch JD et al. Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. 1991 Transplant. Proc. pmid:1721406
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Yamashita K et al. Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. 1999 Feb-Mar Transplant. Proc. pmid:10083526
Alessiani M et al. Pharmacokinetic study of intraarterial local intestinal infusion of tacrolimus. 2000 Transplant. Proc. pmid:10995915
Yamada MF et al. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. 2008 Transplant. Proc. pmid:19100456
Molinaro M et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. 2001 Transplant. Proc. pmid:11377570
Yamanaka K et al. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. 2016 Transplant. Proc. pmid:27234735
van Riemsdijk IC et al. Improvement of cardiovascular risk factors in heart transplant recipients after conversion from cyclosporine to tacrolimus: a role of the TGF-beta system. 2002 Transplant. Proc. pmid:12176606
Franke GH et al. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation. 2006 Transplant. Proc. pmid:16797285
Evans NJ et al. The expression of endothelin and inducible nitric oxide synthase in human renal allografts and their role in chronic renal allograft nephropathy. 2001 Feb-Mar Transplant. Proc. pmid:11267247
Cailhier JF et al. CMV in kidney transplants in the tacrolimus-mycophenolate era. 2001 Feb-Mar Transplant. Proc. pmid:11267255
DeValeria PA et al. FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. 1991 Transplant. Proc. pmid:1721438
Jiang H et al. Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. 1991 Transplant. Proc. pmid:1721439
Dikow R et al. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine. 2004 Transplant. Proc. pmid:15251373
Murase N et al. Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. 1987 Transplant. Proc. pmid:2445081
Makowka L et al. The effect of FK-506 on hyperacute rejection in presensitized rats. 1987 Transplant. Proc. pmid:2445082
Chu Z et al. Influence of immunosuppressive drugs on the development of CD4(+)CD25(high) Foxp3(+) T cells in liver transplant recipients. 2010 Transplant. Proc. pmid:20832552
Jonas S et al. Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation. 1998 Transplant. Proc. pmid:9723433
Dutta S et al. Liposomal tacrolimus and intestinal drug concentration. 1998 Transplant. Proc. pmid:9745533
Perego C et al. Study of the immunosuppressive effect of SMS 201-995 and its synergic action with FK 506. 1998 Transplant. Proc. pmid:9723434
Timmermann W et al. Noninvasive videomicroscopic monitoring of rat small bowel rejection. 1998 Transplant. Proc. pmid:9745537
Morales J et al. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. 2008 Transplant. Proc. pmid:19010240
Wang CH et al. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan. 2004 Transplant. Proc. pmid:15561256
Kahl A et al. Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil. 2001 Feb-Mar Transplant. Proc. pmid:11267473
Rieber J et al. Effects of tacrolimus and cyclosporine on the coronary microcirculation after heart transplantation: a prospective study with serial intracoronary flow measurements. 1998 Transplant. Proc. pmid:9636446
Nielsen FT et al. Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. 1994 Transplant. Proc. pmid:7527946
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947